Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 14, 2013; 19(2): 265-273
Published online Jan 14, 2013. doi: 10.3748/wjg.v19.i2.265
Published online Jan 14, 2013. doi: 10.3748/wjg.v19.i2.265
Table 1 Baseline characteristics of patients with active ulcerative colitis receiving intravenous corticosteroids after oral corticosteroid therapy failure
Total patients (n = 67) | |
Gender (male/female) | 39/28 (58.2/41.8) |
Age (yr) | 35 (13-78) |
Age at diagnosis (yr) | 31 (11-78) |
Disease duration (mo) | 24 (0-132) |
Disease extent | |
Proctitis | 5 (7.5) |
Left-sided colitis | 21 (31.3) |
Extensive colitis | 41 (61.2) |
First attack of UC | 32 (47.8) |
Number of previous flares | 2 (1-4) |
Initial disease activity | |
Full Mayo score | 9 (5-10) |
Partial Mayo score | 6 (3-7) |
Initial prednisolone dose (mg) | |
≥ 30 and < 40 | 35 (52.2) |
≥ 40 | 32 (47.8) |
Duration of oral corticosteroid use (d) | 13 (3-50) |
Maintenance before flare up | |
None/salicylates/azathioprine | 6/47/14 |
Concomitant medications | |
Salicylates | 53 |
Azathioprine | 14 |
CRP (mg/dL) | 10.9 (0.1-153.0) |
ESR (mm/h) | 40.0 (3.0-120.0) |
Hemoglobin (mg/dL) | 11.7 (6.4-16.5) |
Albumin (mg/dL) | 3.6 (2.3-5.0) |
Table 2 Comparison of clinical factors in immediate outcomes of the two groups of active ulcerative colitis patients receiving intravenous corticosteroids after oral corticosteroid therapy failure
Responders (n = 56) | Non-responders1 (n = 11) | P-value | Odds ratio (95%CI) | ||
Univariate | Multivariate | ||||
Gender (M/F) | 32/24 (57.1/42.9) | 7/4 (63.6/36.4) | 0.690 | ||
Age (yr) | 37 (13-78) | 39 (29-50) | 0.458 | ||
Disease duration (mo) | |||||
≤ 24 | 34 (60.7) | 3 (27.3) | 0.041 | 0.123 | 3.38 (0.72-15.88) |
> 24 | 22 (39.3) | 8 (72.7) | |||
First attack of UC | 26 (46.4) | 6 (54.5) | 0.273 | ||
Disease extent | 0.884 | ||||
Proctitis | 4 (7.1) | 1 (9.1) | |||
Left-sided colitis | 17 (30.4) | 4 (36.4) | |||
Extensive colitis | 35 (62.5) | 6 (54.5) | |||
Disease activity | |||||
Full Mayo score (< 9/≥ 9) | 27/24 (52.9/47.1) | 3/8 (27.3/72.7) | 0.122 | ||
Partial Mayo score (< 6/≥ 6) | 14/42 (25/75) | 1/10 (9.1/90.9) | 0.227 | ||
Initial prednisolone dose (mg) | 0.622 | ||||
≥ 30 and < 40 | 29 (51.8) | 6 (54.5) | |||
≥ 40 | 27 (48.2) | 5 (45.5) | |||
Duration of oral corticosteroid use (d) | |||||
≤ 14 | 33 (58.9) | 3 (27.3) | 0.054 | 0.049 | 4.9 (1.01-23.81) |
> 14 | 23 (41.1) | 8 (72.7) | |||
Concomitant medications | 0.809 | ||||
Salicylates | 44 (78.6) | 9 (81.8) | |||
Azathioprine | 12 (21.4) | 2 (18.2) | |||
CRP (mg/dL) | |||||
≤ 8 | 37 (66.1) | 11 (84.6) | 0.303 | ||
> 8 | 19 (33.9) | 2 (15.4) | |||
ESR (mm/h) | 40 (3-120) | 40 (12-83) | 0.999 | ||
Hemoglobin (mg/dL) | |||||
≤ 11 | 18 (32.1) | 8 (72.7) | 0.012 | 0.02 | 0.16 (0.03-0.75) |
> 11 | 38 (67.9) | 3 (27.3) | |||
Albumin (mg/dL) | 3.63 (2.3-5.0) | 3.56 (2.8-4.8) | 0.331 |
Table 3 Comparison of clinical factors in one month outcomes of the two groups of active ulcerative colitis patients receiving intravenous corticosteroids after oral corticosteroid therapy failure
Good responders1(n = 44) | Poor responders2(n = 12) | P-value univariate | |
Gender (M/F) | 24/20 (54.5/45.5) | 8/4 (66.7/33.3) | 0.956 |
Age (yr) | 37 (11-78) | 38 (29-59) | 0.342 |
Disease duration (mo) | |||
≤ 24 | 25 (56.8) | 9 (75) | 0.253 |
> 24 | 19 (43.2) | 3 (3) | |
First attack of UC | 18 (40.9) | 8 (66.7) | 0.113 |
Disease extent | 0.943 | ||
Proctitis | 3 (6.8) | 1 (8.3) | |
Left-sided colitis | 13 (29.5) | 4 (33.3) | |
Extensive colitis | 28 (63.6) | 7 (58.3) | |
Disease activity | |||
Full Mayo score (< 9/≥ 9) | 23/19 (54.8/45.2) | 4/5 (44.4/55.6) | 0.574 |
Partial Mayo score (< 6/≥ 6) | 12/32 (27.3/72.7) | 2/10 (16.7/83.3) | 0.452 |
Initial prednisolone dose (mg) | 0.429 | ||
≥ 30 and < 40 | 24 (54.5) | 5 (41.7) | |
≥ 40 | 20 (45.5) | 7 (58.3) | |
Duration of oral corticosteroid use (d) | |||
≤ 14 | 26 (59.1) | 7 (58.3) | 0.962 |
> 14 | 18 (40.9) | 5 (41.7) | |
Concomitant medications | 0.212 | ||
Salicylates | 33 (75) | 11 (91.7) | |
Azathioprine | 11 (25) | 1 (8.3) | |
CRP (mg/dL) | |||
≤ 8 | 28 (63.6) | 9 (75) | 0.461 |
> 8 | 16 (36.4) | 3 (25) | |
ESR (mm/h) | 40.7 (3-120) | 37.2 (12-83) | 0.464 |
Hemoglobin (mg/dL) | |||
≤ 11 | 15 (34.1) | 3 (25) | 0.550 |
> 11 | 29 (65.9) | 9 (75) | |
Albumin (mg/dL) | 3.6 (2.3-5.0) | 3.45 (2.6-4.8) | 0.295 |
Table 4 Comparison of clinical factors in three month outcomes of the two groups of active ulcerative colitis patients receiving intravenous corticosteroids after oral corticosteroid therapy failure
Good responders1(n = 37) | Poor responders2(n = 18) | P-value univariate | |
Gender (M/F) | 21/16 (56.8/43.2) | 10/8 (55.6/44.4) | 0.933 |
Age (yr) | 35 (13-78) | 41 (20-62) | 0.146 |
Disease duration (mo) | |||
≤ 24 | 22 (59.5) | 12 (66.7) | 0.606 |
> 24 | 15 (40.5) | 6 (33.3) | |
First attack of UC | 15 (40.5) | 10 (55.6) | 0.294 |
Disease extent | 0.317 | ||
Proctitis | 3 (8.1) | 1 (5.6) | |
Left-sided colitis | 9 (24.3) | 8 (44.4) | |
Extensive colitis | 25 (67.6) | 9 (50) | |
Disease activity | |||
Full Mayo score (< 9/≥ 9) | 20/14 (58.8/41.2) | 7/9 (43.8/56.3) | 0.318 |
Partial Mayo score (< 6/≥ 6) | 11/26 (29.7/70.3) | 3/15 (16.7/83.3) | 0.297 |
Initial prednisolone dose (mg) | 0.925 | ||
≥ 30 and < 40 | 19 (51.4) | 9 (50) | |
≥ 40 | 18 (48.6) | 9 (50) | |
Duration of oral corticosteroid use (d) | 0.639 | ||
≤ 14 | 23 (62.2) | 10 (55.6) | |
> 14 | 14 (37.8) | 8 (44.4) | |
Concomitant medications | 0.180 | ||
Salicylates | 27 (73) | 16 (88.9) | |
Azathioprine | 10 (27) | 2 (11.1) | |
CRP (mg/dL) | |||
≤ 8 | 24 (64.9) | 12 (66.7) | 0.895 |
> 8 | 13 (35.1) | 6 (33.3) | |
ESR (mm/h) | 36.9 (3-120) | 47.6 (6-120) | 0.251 |
Hemoglobin (mg/dL) | |||
≤ 11 | 14 (37.8) | 4 (22.2) | 0.247 |
> 11 | 23 (62.2) | 14 (77.8) | |
Albumin (mg/dL) | 3.73 (2.7-5.0) | 3.44 (2.3-4.6) | 0.082 |
Table 5 Comparison of clinical factors in one year outcomes of the two groups of active ulcerative colitis patients receiving intravenous corticosteroids after oral corticosteroid therapy failure
Good responders1(n = 25) | Poor responders2(n = 29) | P-value univariate | |
Gender (M/F) | 15/10 (60/40) | 16/13 (55/45) | 0.721 |
Age (yr) | 35 (16-78) | 39 (13-64) | 0.445 |
Disease duration (mo) | 30 (0-84) | 29 (0-120) | 0.325 |
≤ 24 | 14 (56) | 20 (69) | |
> 24 | 11 (44) | 9 (31) | |
First attack of UC | 9 (36) | 15 (51.7) | 0.248 |
Disease extent | 0.304 | ||
Proctitis | 1 (4) | 3 (10.3) | |
Left-sided colitis | 6 (24) | 11 (37.9) | |
Extensive colitis | 18 (72) | 15 (51.7) | |
Disease activity | |||
Full Mayo score (< 9/≥ 9) | 15/9 (62.5/37.5) | 11/14 (44/56) | 0.195 |
Partial Mayo score (< 6/≥ 6) | 9/16 (36/64) | 4/25 (13.8/86.2) | 0.057 |
Initial prednisolone dose (mg) | 0.785 | ||
≥ 30 and < 40 | 13 (52) | 14 (48.3) | |
≥ 40 | 12 (48) | 15 (51.7) | |
Duration of oral corticosteroid use (d) | 0.337 | ||
≤ 14 | 17 (68) | 16 (55.2) | |
> 14 | 8 (32) | 13 (44.8) | |
Concomitant medications | 0.771 | ||
Salicylates | 19 (76) | 23 (79.3) | |
Azathioprine | 6 (24) | 6 (20.7) | |
CRP (mg/dL) | |||
≤ 8 | 16 (64%) | 19 (65.5) | 0.907 |
> 8 | 9 (36%) | 10 (34.5) | |
ESR (mm/h) | 34.1 (4-81) | 46.3 (3-120) | 0.171 |
Hemoglobin (mg/dL) | |||
≤ 11 | 9 (36) | 8 (27.6) | 0.507 |
> 11 | 16 (64) | 21 (72.4) | |
Albumin (mg/dL) | 3.8 (2.7-4.7) | 3.57 (2.3-5.0) | 0.230 |
- Citation: Jeon HH, Lee HJ, Jang HW, Yoon JY, Jung YS, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis. World J Gastroenterol 2013; 19(2): 265-273
- URL: https://www.wjgnet.com/1007-9327/full/v19/i2/265.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i2.265